NASDAQ | VICL: 2.66  +0.01
investors
Investors

News Releases

DateSubject
June 15, 2017 Vical to Provide Company Update at the 2017 BIO International Convention
June 5, 2017 Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
May 23, 2017 Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
May 15, 2017 Vical Reports First Quarter 2017 Financial Results
May 8, 2017 Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
May 2, 2017 Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
April 24, 2017 Vical to Host Virtual Research & Development Day on May 2, 2017
April 19, 2017 Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
March 10, 2017 Vical to Provide Company Update at the 29th Annual ROTH Conference
March 9, 2017 Vical to Provide Company Update at BIO Asia International Conference
March 9, 2017 Vical Reports Fourth Quarter 2016 Financial Results
March 2, 2017 Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results
February 24, 2017 Vical Provides Company Update at Biocom's Global Life Science Partnering Conference
February 7, 2017 Vical Provides Company Update at BIO CEO and Investor Conference

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.